Drug Overview

Savolitinib is an advanced, investigational cancer medication created to fight specific types of tumors, particularly in the lungs and kidneys. It is taken by mouth as a daily tablet. Because it is highly specialized, it is currently being studied in clinical trials across the United States and Europe, though it has already received conditional approvals in certain global markets under different brand names.

As an experimental treatment in the US, it is not available at a standard local pharmacy. Patients can access this medication by participating in approved medical research studies guided by an oncologist.

• Generic name: Savolitinib (also known in research as AZD6094, HMPL-504, or volitinib)
• US Brand names: None currently approved in the US (Marketed as Orpathys in China)
• Drug Class: c-MET receptor tyrosine kinase inhibitor, Small molecule inhibitor
• Route of Administration: Oral (taken by mouth as a tablet)
• FDA Approval Status: Investigational (Granted Fast Track Designation by the FDA; not yet fully approved for standard public medical use in the United States)

What Is It and How Does It Work? (Mechanism of Action)

Savolitinib is a precision medicine that acts as a Targeted Therapy and possesses Smart Drug characteristics. Instead of attacking all rapidly dividing cells in the body like traditional chemotherapy, this medication is precision-engineered to locate and disable a very specific communication tower on the surface of cancer cells.

At the molecular level, savolitinib targets a receptor protein known as the mesenchymal-epithelial transition factor, or c-MET. In healthy cells, c-MET acts as a normal receiver antenna. When a natural body chemical called hepatocyte growth factor binds to it, the antenna sends signals down into the cell through specific communication pathways (such as the PI3K/AKT and MAPK/ERK pathways) to tell the cell to grow and repair tissues.

However, in many cancer cells, this system is broken. Genetic errors, such as MET exon 14 skipping mutations or MET gene amplification, cause the c-MET antenna to become permanently stuck in the “on” position. The cancer cell receives a constant, unstoppable signal to multiply and spread.

Savolitinib works by entering the cancer cell and binding directly to the ATP-binding pocket of the c-MET receptor (specifically interacting with the Y1230 amino acid residue). By physically plugging this pocket, the drug cuts off the energy supply that the receptor needs to send its signals. Once the PI3K/AKT and MAPK/ERK pathways are shut down, the cancer cells lose their growth signals, stop dividing, and are forced into a natural self-destruct cycle called apoptosis.

FDA Approved Clinical Indications

Because savolitinib is currently an investigational medication in the United States, it does not have official FDA-approved indications for the general public. It is, however, being extensively evaluated in clinical trials for the following conditions:

Oncological uses

• Investigational treatment for locally advanced or metastatic non-small cell lung cancer harboring MET exon 14 skipping mutations.
• Investigational treatment for advanced non-small cell lung cancer with EGFR mutations and MET amplification that has stopped responding to prior targeted therapies (such as osimertinib).
• Investigational treatment for papillary renal cell carcinoma (a type of kidney cancer) driven by MET alterations.
• Investigational treatment for advanced gastric (stomach) cancer with MET gene amplification.

Non-oncological

• There are currently no non-oncological uses for this medication.

Dosage and Administration Protocols

Because savolitinib is an experimental therapy, exact dosages are strictly determined by the specific clinical trial protocol and the patient’s body weight. The table below outlines standard dosing frameworks observed in recent major clinical trials.

Dose Adjustments

Because savolitinib is processed and cleared by the liver, careful dose adjustments are mandatory for patients who show signs of liver stress during treatment. If routine blood tests reveal significant elevations in liver enzymes (such as AST or ALT), clinical trial doctors will pause the medication until the liver recovers. Once healed, the drug may be restarted at a permanently reduced dose, such as lowering a 600-milligram dose to 400 milligrams. Patients with pre-existing severe hepatic (liver) insufficiency may be excluded from certain trials or require highly customized, lower starting doses.

Clinical Efficacy and Research Results

Clinical research data from the 2020 to 2025 period have highlighted the strong potential of savolitinib, particularly for patients with lung and kidney cancers that resist standard treatments.

In the global Phase 3 SACHI trial (data reported in 2024 and 2025) for patients with advanced non-small cell lung cancer whose disease progressed after taking standard EGFR inhibitors, researchers combined savolitinib with the drug osimertinib. This combination resulted in a median progression-free survival of 7.2 months compared to only 4.2 months for patients who received standard chemotherapy. Furthermore, the overall response rate (the percentage of patients whose tumors shrank significantly) was 63.2 percent for the savolitinib group, compared to 36.2 percent for the chemotherapy group.

In long-term studies evaluating savolitinib as a standalone treatment for lung cancer patients specifically carrying the MET exon 14 skipping mutation, the median overall survival reached 12.5 months, providing a vital new option for a difficult-to-treat demographic. Additionally, in the CALYPSO Phase 2 trial for papillary kidney cancer, combination therapy involving savolitinib resulted in a tumor response rate of 53 percent in patients who specifically carried the MET gene alteration.

Safety Profile and Side Effects

Like all potent targeted therapies, savolitinib carries a risk of side effects. Patients in clinical trials are monitored constantly to ensure their safety.

Black Box Warning:

Because this drug is investigational and not available on the regular market, it does not currently carry an official FDA Black Box Warning.

Common side effects

These side effects have been reported in greater than 10 percent of patients during clinical trials:

• Peripheral edema (fluid retention causing swelling in the hands, ankles, and feet)
• Nausea and vomiting
• Fatigue and general weakness
• Elevated liver enzymes (found during routine blood tests)
• Decreased appetite
• Diarrhea

Serious adverse events:

• Severe hepatotoxicity (drug-induced liver injury that can be dangerous if unmonitored)
• Hypersensitivity reactions (severe allergic responses including rash and fever)
• Interstitial lung disease (a rare but life-threatening inflammation of the lung tissue that makes breathing very difficult)

Management strategies:

Patient safety relies on proactive management. To handle peripheral edema, doctors often recommend elevating the legs and may prescribe mild diuretics (water pills) to help flush out excess fluid. For nausea, standard anti-emetic medications are provided. Because liver toxicity is a primary concern, patients must undergo frequent liver function blood tests. If liver enzymes rise to dangerous levels, the medical team will immediately halt the drug to prevent permanent organ damage. If a patient develops a sudden, unexplained dry cough or shortness of breath, they must be evaluated instantly for interstitial lung disease.

Research Areas

While savolitinib is not currently used directly with stem cell transplants, it is highly relevant to advanced research concerning the tumor microenvironment and drug resistance. Cancer cells often mutate to escape targeted therapies. Researchers are using liquid biopsies (analyzing tumor DNA floating in the blood) to track how cancer stem cells create new “escape route” mutations (such as MET D1228 or Y1230C) when exposed to savolitinib. By understanding these resistance mechanisms, scientists are learning how to combine savolitinib with immunotherapies (like durvalumab) to create a multi-layered defense that destroys hidden cancer cells and prevents the tumor from growing back.

Patient Management and Practical Recommendations

Participating in a savolitinib clinical trial requires strict adherence to medical guidelines and excellent communication with the oncology team.

Pre treatment tests to be performed:

• Advanced genetic testing (such as Next-Generation Sequencing) of the tumor tissue or blood to confirm the presence of MET exon 14 skipping mutations or MET amplification.
• Comprehensive metabolic panels to establish baseline liver and kidney function.
• A complete blood count to evaluate overall hematologic health.
• An electrocardiogram to monitor the electrical rhythm of the heart.

Precautions during treatment:

Patients must be highly vigilant regarding fluid retention. Monitoring daily weight can help catch peripheral edema early before it becomes severe. Patients must also be aware of the signs of liver stress, which include yellowing of the eyes or skin (jaundice), dark urine, or severe pain in the upper right side of the stomach.

Do’s and Don’ts list:

• Do take the medication at the same time every day to maintain steady levels in your bloodstream.
• Do weigh yourself every morning and report any sudden weight gain to your clinical trial doctor immediately.
• Do report any new breathing difficulties, fevers, or severe rashes to your medical team right away.
• Don’t eat grapefruit or drink grapefruit juice, as the natural enzymes in grapefruit block the liver from processing the drug correctly, leading to toxic build-up.
• Don’t start any new over-the-counter pain medicines, herbal supplements, or vitamins without getting explicit permission from your oncologist first.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Savolitinib is an investigational medication and is not approved by the Food and Drug Administration to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional or your clinical trial oncologist before making any decisions regarding your cancer treatment, managing side effects, or participating in a clinical research study.